In 2022, Upstaza, rAAV2-hAADC, was approved for treating aromatic l-amino acid decarboxylase (AADC) deficiency, marking the first gene therapy targeting the brain directly. Here, DDC is linked to hyperinsulinemic hypoglycemia, familial, 4.